Novartis Pharma S.A.E and Cleopatra Hospitals Group sign an MoC

Novartis Pharma S.A.E and Cleopatra Hospitals Group sign an MoC

- Dr. Ahmed Sharaf: Cardiovascular diseases (CVD) account for 46% of total deaths in Egypt

- Dr. Sherif Amin: We aim to understand the needs of patients and to come up with solutions that meet those needs through partnerships and commitment to providing innovative medicines and providing the latest global treatment solutions to the Egyptian patient.

- Dr. Ahmed Ezz El-Din: We are working to achieve the common goal of accelerating the ASCVD patient’s access to innovative treatment for the disease as part of the group’s efforts to provide the latest international treatemens.

- Dr. Ahmed Ezz El-Din: Cleopatra Hospitals Group is constantly seeking the latest medical treatements and medical equiprments that help get the group’s patients the latest international medical practices

Cairo: Novartis Pharma S.A.E (Novartis Pharma Egypt), the global leader in the healthcare industry, signed a memorandum of collaboration (MoC) with Cleopatra Hospitals Group (CHG), Egypt’s best provider of medical and healthcare services. This agreement aims to support scientific programs, continuous medical education, in addition to raising patients’ awareness, and supporting digital means to find preventive solutions for early detection CVD and providing ideal care for these patients, by providing the latest treatments and the best possible services throughout their treatment.

The MoC